ClearPoint Neuro Performance degli utili passati
Criteri Il passato verificati 0/6
Gli utili di ClearPoint Neuro sono diminuiti a un tasso medio annuo di -16.1%, mentre il settore Medical Equipment ha visto gli utili crescere a un tasso medio annuo di 13.6%. I ricavi sono cresciuti crescere a un tasso medio annuo di 20.3%.
Informazioni chiave
-16.06%
Tasso di crescita degli utili
-8.43%
Tasso di crescita dell'EPS
| Medical Equipment Crescita del settore | 8.90% |
| Tasso di crescita dei ricavi | 20.33% |
| Rendimento del capitale proprio | -154.27% |
| Margine netto | -71.57% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • May 26
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Upside Potential
Narrative Update: ClearPoint Neuro Analyst Price Target Revision Analysts now set a $22 price target for ClearPoint Neuro, down from $25. This reflects slightly lower modeled revenue growth and profit margins, along with a modestly reduced future P/E assumption, even as recent research highlights the company’s broad base of more than 60 biopharma partners and multiple clinical-stage programs with expedited review designations.Seeking Alpha • Apr 29
ClearPoint Neuro: Temporary Headwinds Don't Change The Long-Term Outlook
Summary ClearPoint's stock has come under significant pressure in recent months following weaker 2026 revenue guidance and further regulatory uncertainty. Despite near-term headwinds, a step change in revenue remains likely as partner therapies are commercialized over the next few years. Independent of this, ClearPoint's forward revenue multiple looks increasingly reasonable given the company's strong competitive positioning and solid growth. Read the full article on Seeking AlphaAggiornamento della narrazione • Apr 20
CLPT: Biopharma Partnerships Will Drive Future Intracranial Program Adoption
ClearPoint Neuro's analyst price target has shifted by $2 as analysts weigh the recent FDA feedback on a partner's program in relation to the company's more than 60 active biopharma relationships and multiple expedited intracranial programs. Analyst Commentary Bullish Takeaways Bullish analysts see the reset price target of $18 per share as supported by what they view as a base business valuation of $12 per share, with additional value tied to pipeline and execution on intracranial programs.Aggiornamento della narrazione • Apr 06
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Platform Adoption
Analysts have adjusted their price target on ClearPoint Neuro to $25.00, reflecting updated assumptions around the discount rate, margin expectations, and long term P/E benchmarks following recent research commentary. Analyst Commentary Recent research commentary on ClearPoint Neuro highlights a mix of optimism around the core business and caution linked to regulatory outcomes in partner programs, which feeds directly into updated valuation work and risk assumptions.Aggiornamento della narrazione • Mar 22
CLPT: Broad Biopharma Partnerships And Intracranial Programs Will Drive Future Upside
Analysts have raised their price target on ClearPoint Neuro to $25 from $24, citing the company’s broad base of more than 60 biopharma partners and multiple clinical-stage intracranial programs as key supports for the updated valuation framework. Analyst Commentary Recent research on ClearPoint Neuro reflects a mix of renewed optimism and lingering caution, with analysts updating their valuation work after regulatory feedback on a key partner trial and reassessing the base business.
Nuova narrazione • Mar 21
Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders
Catalysts About ClearPoint Neuro ClearPoint Neuro provides minimally invasive neurosurgery systems and tools that support drug, cell and gene therapy delivery to the brain. What are the underlying business or industry changes driving this perspective?Aggiornamento della narrazione • Mar 06
CLPT: Broad Biopharma Partnerships Will Support Future Neurology Platform Upside
Analysts have reduced their fair value estimate for ClearPoint Neuro from $29 to $24 and highlighted a lower $18 Street price target, citing higher perceived risk after the FDA feedback on a partner program, while still pointing to a broad biopharma customer base and multiple clinical-stage collaborations as key supports for the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts still see support for the updated valuation from more than 60 active biopharma partners, which suggests a diversified customer base rather than reliance on a single program.
Nuova narrazione • Mar 06
IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential
Catalysts About ClearPoint Neuro ClearPoint Neuro develops and sells neurosurgical navigation, drug delivery and cranial access technologies used across preclinical research, clinical trials and hospital procedures. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Nov 10
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues
The ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price has softened a substantial 39% over the previous 30 days...Articolo di analisi • Nov 03
Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Sep 25
Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 84% after a shaky period...Articolo di analisi • May 04
After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Those holding ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares would be relieved that the share price has rebounded 31% in...Seeking Alpha • Apr 29
ClearPoint Neuro: Fundamentals Continue To Strengthen
Summary ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance. I continue to believe ClearPoint is an attractive investment opportunity, but its high revenue multiple, current lack of profitability and market volatility mean risk is elevated. Read the full article on Seeking Alpha
Nuova narrazione • Mar 29
Cell And Gene Therapy Delivery Will Expand Global Partnerships
Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements.Articolo di analisi • Feb 14
After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have continued their recent momentum with a 25% gain in the last month...Articolo di analisi • Dec 10
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shareholders have had their patience rewarded with a 26% share price jump in the...Articolo di analisi • Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Despite an already strong run, ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have been powering on, with a gain of 28...Articolo di analisi • Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 26% after a shaky period...Articolo di analisi • May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) just released its latest first-quarter results and things are looking bullish...Seeking Alpha • Apr 25
ClearPoint Neuro: Macro-Induced Multiple Compression
Summary ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates. The company is expanding its product portfolio and driving adoption of existing products with new software releases and FDA clearances. The recent capital raise should be sufficient to see the ClearPoint through to profitability. ClearPoint's valuation is modest given the company's rapid growth and expanding product portfolio. Read the full article on Seeking AlphaArticolo di analisi • Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for ClearPoint Neuro is US$4.02 based on 2 Stage Free Cash Flow to Equity Current...Articolo di analisi • Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Shareholders of ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) will be pleased this week, given that the stock price is up 19...Articolo di analisi • Jan 04
Should You Investigate ClearPoint Neuro, Inc. (NASDAQ:CLPT) At US$6.18?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ), is not the largest company out there, but it received a lot of attention from a...Articolo di analisi • Dec 06
Does ClearPoint Neuro (NASDAQ:CLPT) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Nov 06
Is There An Opportunity With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 41% Undervaluation?
Key Insights The projected fair value for ClearPoint Neuro is US$10.27 based on 2 Stage Free Cash Flow to Equity...Articolo di analisi • Aug 18
Is ClearPoint Neuro (NASDAQ:CLPT) Using Debt In A Risky Way?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come ClearPoint Neuro guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 41 | -29 | 35 | 15 |
| 31 Dec 25 | 37 | -26 | 31 | 14 |
| 30 Sep 25 | 34 | -23 | 30 | 14 |
| 30 Jun 25 | 34 | -22 | 29 | 14 |
| 31 Mar 25 | 32 | -21 | 28 | 13 |
| 31 Dec 24 | 31 | -19 | 26 | 12 |
| 30 Sep 24 | 30 | -18 | 25 | 12 |
| 30 Jun 24 | 28 | -18 | 25 | 11 |
| 31 Mar 24 | 26 | -21 | 25 | 11 |
| 31 Dec 23 | 24 | -22 | 24 | 12 |
| 30 Sep 23 | 22 | -22 | 23 | 12 |
| 30 Jun 23 | 22 | -21 | 22 | 12 |
| 31 Mar 23 | 21 | -18 | 21 | 11 |
| 31 Dec 22 | 21 | -16 | 19 | 11 |
| 30 Sep 22 | 20 | -16 | 18 | 11 |
| 30 Jun 22 | 19 | -16 | 18 | 11 |
| 31 Mar 22 | 17 | -16 | 16 | 11 |
| 31 Dec 21 | 16 | -14 | 15 | 9 |
| 30 Sep 21 | 16 | -12 | 14 | 8 |
| 30 Jun 21 | 15 | -9 | 13 | 7 |
| 31 Mar 21 | 14 | -7 | 11 | 5 |
| 31 Dec 20 | 13 | -7 | 11 | 5 |
| 30 Sep 20 | 12 | -7 | 10 | 4 |
| 30 Jun 20 | 12 | -6 | 10 | 3 |
| 31 Mar 20 | 12 | -6 | 10 | 3 |
| 31 Dec 19 | 11 | -6 | 9 | 3 |
| 30 Sep 19 | 10 | -5 | 8 | 3 |
| 30 Jun 19 | 9 | -5 | 8 | 2 |
| 31 Mar 19 | 8 | -6 | 8 | 2 |
| 31 Dec 18 | 7 | -6 | 8 | 2 |
| 30 Sep 18 | 7 | -7 | 8 | 2 |
| 30 Jun 18 | 7 | -7 | 8 | 2 |
| 31 Mar 18 | 7 | -7 | 8 | 3 |
| 31 Dec 17 | 7 | -7 | 8 | 3 |
| 30 Sep 17 | 7 | -7 | 8 | 3 |
| 30 Jun 17 | 7 | -8 | 8 | 3 |
| 31 Mar 17 | 6 | -8 | 8 | 3 |
| 31 Dec 16 | 6 | -8 | 8 | 3 |
| 30 Sep 16 | 6 | -8 | 8 | 3 |
| 30 Jun 16 | 5 | -5 | 8 | 2 |
| 31 Mar 16 | 5 | -7 | 8 | 2 |
| 31 Dec 15 | 5 | -8 | 8 | 2 |
| 30 Sep 15 | 4 | -9 | 9 | 2 |
| 30 Jun 15 | 3 | -13 | 9 | 3 |
Guadagni di qualità: CLPT al momento non è redditizia.
Margine di profitto in crescita: CLPT al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: CLPT non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 16.1% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di CLPT nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: CLPT non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Medical Equipment ( 14.8% ).
Rendimento del capitale proprio
ROE elevato: CLPT ha un Return on Equity negativo ( -154.27% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/01 06:02 |
| Prezzo dell'azione a fine giornata | 2026/05/29 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
ClearPoint Neuro, Inc. è coperta da 7 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |